PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.91%
Negative revenue growth while 3141.T stands at 3.79%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
0.58%
Gross profit growth under 50% of 3141.T's 5.27%. Michael Burry would be concerned about a severe competitive disadvantage.
0.43%
EBIT growth 75-90% of 3141.T's 0.55%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
-2.15%
Negative operating income growth while 3141.T is at 18.01%. Joel Greenblatt would press for urgent turnaround measures.
-2.62%
Negative net income growth while 3141.T stands at 32.13%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2.63%
Negative EPS growth while 3141.T is at 32.20%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.63%
Negative diluted EPS growth while 3141.T is at 32.20%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.03%
10Y revenue/share CAGR at 50-75% of 3141.T's 23.57%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-4.03%
Negative 5Y CAGR while 3141.T stands at 23.57%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-25.88%
Negative 3Y CAGR while 3141.T stands at 15.79%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
90.97%
Below 50% of 3141.T's 256.46%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
0.73%
Below 50% of 3141.T's 256.46%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-24.36%
Negative 3Y CAGR while 3141.T is 117.93%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
63.24%
10Y equity/share CAGR at 50-75% of 3141.T's 92.54%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.18%
Negative 3Y equity/share growth while 3141.T is at 65.38%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.78%
3Y dividend/share CAGR at 75-90% of 3141.T's 62.50%. Bill Ackman wants overhead or revenue enhancements to match competitor's dividend growth.
5.88%
AR growth well above 3141.T's 3.21%. Michael Burry fears inflated revenue or higher default risk in the near future.
7.68%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.22%
Negative asset growth while 3141.T invests at 1.83%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.68%
1.25-1.5x 3141.T's 3.54%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-9.08%
We’re deleveraging while 3141.T stands at 70.34%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.39%
We expand SG&A while 3141.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.